Literature DB >> 22286104

Multiple sclerosis and risk of venous thromboembolism: a population-based cohort study.

Steffen Christensen1, Dóra Körmendiné Farkas, Lars Pedersen, Montserrat Miret, Christian Fynbo Christiansen, Henrik Toft Sørensen.   

Abstract

BACKGROUND: Multiple sclerosis (MS) patients may be at increased risk of venous thromboembolism (VTE), but evidence is limited.
OBJECTIVES: To examine long-term risk of VTE among MS patients. PATIENTS AND METHODS: We conducted a population-based cohort study among 17,418 Danish MS patients and 87,090 comparison cohort members from the general population. Data on MS, VTE and comorbidities were obtained from the Danish National Registry of Patients including all admissions to Danish hospitals since 1977. We computed cumulative risks for VTE and adjusted incidence rate ratios (IRRs).
RESULTS: A total of 34 (0.2%) MS patients and 36 (0.04%) comparison cohort members had a deep venous thrombosis (DVT) within 1 year following the date of initial MS diagnosis/index date [adjusted IRR = 3.02 (95% CI: 2.14-4.27)]. During this period, 16 (0.09%) MS patients and 26 (0.03%) comparison cohort members had a documented pulmonary embolism (PE) [adjusted IRR = 2.85 (95% CI: 1.72-4.70)]. During the subsequent up to 29 years, 315 (1.9% of MS patients alive at year 1) MS patients had a record of a DVT [adjusted IRR = 2.28 (95% CI: 2.01-2.59)] and 129 (0.8%) had PE [IRR = 1.58 (95% CI: 1.31-1.92].
CONCLUSION: MS is a risk factor for VTE, but the absolute risk is low.
Copyright © 2012 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2012        PMID: 22286104     DOI: 10.1159/000335496

Source DB:  PubMed          Journal:  Neuroepidemiology        ISSN: 0251-5350            Impact factor:   3.282


  12 in total

1.  Relationship between the Increased Haemostatic Properties of Blood Platelets and Oxidative Stress Level in Multiple Sclerosis Patients with the Secondary Progressive Stage.

Authors:  Agnieszka Morel; Michał Bijak; Elżbieta Miller; Joanna Rywaniak; Sergiusz Miller; Joanna Saluk
Journal:  Oxid Med Cell Longev       Date:  2015-04-29       Impact factor: 6.543

Review 2.  Aspirin and multiple sclerosis.

Authors:  Sheila Tsau; Mitchell R Emerson; Sharon G Lynch; Steven M LeVine
Journal:  BMC Med       Date:  2015-06-29       Impact factor: 8.775

Review 3.  Demyelinating and thrombotic diseases of the central nervous system: common pathogenic and triggering factors.

Authors:  Tatiana Koudriavtseva; Rosaria Renna; Domenico Plantone; Caterina Mainero
Journal:  Front Neurol       Date:  2015-03-24       Impact factor: 4.003

4.  Thrombin generation correlates with disease duration in multiple sclerosis (MS): Novel insights into the MS-associated prothrombotic state.

Authors:  Martin Em Parsons; Karen O'Connell; Seamus Allen; Karl Egan; Paulina B Szklanna; Christopher McGuigan; Fionnuala Ní Áinle; Patricia B Maguire
Journal:  Mult Scler J Exp Transl Clin       Date:  2017-12-26

Review 5.  Pro-Thrombotic Activity of Blood Platelets in Multiple Sclerosis.

Authors:  Joanna Saluk-Bijak; Angela Dziedzic; Michal Bijak
Journal:  Cells       Date:  2019-02-01       Impact factor: 6.600

6.  Increased level of fibrinogen chains in the proteome of blood platelets in secondary progressive multiple sclerosis patients.

Authors:  Michal Bijak; Alicja Olejnik; Bozena Rokita; Agnieszka Morel; Angela Dziedzic; Elzbieta Miller; Joanna Saluk-Bijak
Journal:  J Cell Mol Med       Date:  2019-03-05       Impact factor: 5.310

7.  Myeloproliferative neoplasms in five multiple sclerosis patients.

Authors:  Sigrun Thorsteinsdottir; Ole Weis Bjerrum; Hans Carl Hasselbalch
Journal:  Leuk Res Rep       Date:  2013-07-31

Review 8.  Thrombotic processes in multiple sclerosis as manifestation of innate immune activation.

Authors:  Tatiana Koudriavtseva
Journal:  Front Neurol       Date:  2014-07-07       Impact factor: 4.003

9.  Oxidative Damage of Blood Platelets Correlates with the Degree of Psychophysical Disability in Secondary Progressive Multiple Sclerosis.

Authors:  Angela Dziedzic; Agnieszka Morel; Elzbieta Miller; Michal Bijak; Tomasz Sliwinski; Ewelina Synowiec; Michal Ceremuga; Joanna Saluk-Bijak
Journal:  Oxid Med Cell Longev       Date:  2020-06-17       Impact factor: 6.543

10.  Serious safety events in rituximab-treated multiple sclerosis and related disorders.

Authors:  Brandi L Vollmer; Asya I Wallach; John R Corboy; Karolina Dubovskaya; Enrique Alvarez; Ilya Kister
Journal:  Ann Clin Transl Neurol       Date:  2020-08-06       Impact factor: 4.511

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.